

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request cder_mpl1r_wp085

Request ID: cder_mpl1r_wp085_nsdv_v01

Request Description: The purpose of this study was to understand how biologics, their biosimilars, and related drugs are coded for reimbursement, and therefore appear in claims data. This report contains estimates of utilization of medications of interest in Sentinel Distributed Database (SDD). This is report 1 of 2. Report 2 contains estimates of the distribution of days supplied per dispensing for the medical products of interest, and descriptive statistics for gaps between treatment episodes in the SDD.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 5.4.3.

Data Source: We used data from 17 Data Partners contributing to the SDD in this report. This request was distributed to the Data Partners on June 29, 2018 and includes data from January 1, 2015 to January 31, 2018. See Appendix A for a list of the dates of available data for each Data Partner.

Study Design: This request was designed to calculate background rates. The number of qualifying patients with the exposures of interest were calculated overall and by year-month stratification.

Exposures of Interest: The exposures of interest were the biologic Neupogen, its biosimilar Zarxio, and related drugs Granix and Neulasta; and the biologic Remicade and its biosimilars Inflectra and Renflexis. We defined these exposures using Level II Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). In the Table 3 series, we defined exposures to Remicade, Inflectra and Renflexis using both HCPCS and NDCs. See Appendix B for procedure codes and Appendix C for non-proprietary and brand names of medical products used to define these exposures.

Cohort Eligibility Criteria: For patients included in Tables 1 and 2, we required enrollment in plans with medical and drug coverage, with gaps in coverage of up to 45 days. For the baseline tables (Table 3 series), we required patients to be enrolled in plans with medical and drug coverage for at least 365 days prior to their index date, during which gaps in coverage of up to 45 days were allowed. Patients of all ages were included in this study.

Baseline Characteristics: This report contains baseline tables for patients exposed to Remicade, Inflectra and Renflexis. We assessed the following characteristics during the baseline period: age, sex, year, gastrointestinal (GI) conditions, non-gastrointestinal (non-GI) conditions, no GI conditions and no non-GI conditions. We examined the three condition-related characteristics during two separate time periods: -365 days through index date and -365 days through 365 days post-index date. GI conditions include ulcerative colitis and Crohn's disease. Non-GI conditions include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. Please refer to Appendix D for specific diagnosis codes used to define characteristics.

Please refer to Appendix E for detailed specifications of parameters used in the analyses for this request.

Limitations: Algorithms to define exposures and characteristics are imperfect and, therefore, they may be misclassified. Therefore, data should be interpreted with this limitation in mind. We were unable to examine exposures to Inflectra and Renflexis by HCPCS codes specific to these medications due to them being procedure codes with modifiers (Q5102-ZB and Q5102-ZC respectively). Therefore, exposure to infliximab via Q5102 (Injection, infliximab, biosimilar, 10 mg) without modifiers was reported instead.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1</u>	Summary of Prevalent Use of Biologics and Biosimilars in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, Overall
<u>Table 2</u>	Summary of Prevalent Use of Biologics and Biosimilars in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month
<u>Table 3a</u>	Baseline Characteristics Users of Remicade in the Sentinel Distributed Database (SDD) between January 1, 2015 to January 31, 2018
<u>Table 3b</u>	Baseline Characteristics Users of Inflectra in the Sentinel Distributed Database (SDD) between January 1, 2015 to January 31, 2018
<u>Table 3c</u>	Baseline Characteristics Users of Renflexis in the Sentinel Distributed Database (SDD) between January 1, 2015 to January 31, 2018
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 31, 2018)
<u>Appendix B</u>	List of Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures of Interest in this Request
<u>Appendix C</u>	List of Non-Proprietary and Brand Names of Medical Products Used to Define Exposures of Interest in this Request
<u>Appendix D</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request
<u>Appendix E</u>	Specifications Defining Parameters in the Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, Overall

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
Identified via Healthcare Common Procedure Coding System (HCPCS)								
Neupogen (J1440) Use	*****	*****	7.00	*****	7.00	105,963,363	0.00	150,219,314.8
Neupogen (J1441) Use	*****	*****	1.00	*****	1.00	105,963,363	0.00	150,219,314.8
Neupogen (J1442) Use	39,329	244,174	6.21	244,809	6.22	105,963,363	37.12	150,219,314.8
Neulasta (J2505) Use	123,868	468,482	3.78	468,973	3.79	105,963,363	116.90	150,219,314.8
Granix (J1446) Use	8,047	39,067	4.85	39,105	4.86	105,963,363	7.59	150,219,314.8
Granix (J1447) Use	5,165	37,252	7.21	37,296	7.22	105,963,363	4.87	150,219,314.8
Zarxio (Q5101) Use	9,118	76,903	8.43	77,043	8.45	105,963,363	8.60	150,219,314.8
Remicade (J1745) Use	76,654	594,500	7.76	595,842	7.77	105,963,363	72.34	150,219,314.8
Infliximab (Q5102) Use	*****	*****	2.49	*****	2.52	105,963,363	1.03	150,219,314.8
Identified via National Drug Codes (NDCs)								
Neupogen dispensings Use	16,696	49,514	2.97	49,514	2.97	105,963,363	15.76	150,219,314.8
Neulasta dispensings Use	8,719	29,336	3.36	29,336	3.36	105,963,363	8.23	150,219,314.8
Granix dispensings Use	772	1,782	2.31	1,782	2.31	105,963,363	0.73	150,219,314.8
Zarxio dispensings Use	7,735	27,723	3.58	27,723	3.58	105,963,363	7.30	150,219,314.8
Remicade dispensings Use	5,743	39,777	6.93	39,777	6.93	105,963,363	5.42	150,219,314.8
Inflectra dispensings Use	157	320	2.04	320	2.04	105,963,363	0.15	150,219,314.8
Renflexis dispensings Use	0	0	-	0	-	105,963,363	0.00	150,219,314.8
Combinations, HCPCS Occurring Within -3 through +3 days of a Dispensing								
J3490 + Neupogen NDCs	496	939	1.89	939	1.89	105,963,363	0.47	150,219,314.8
J3490 + Neulasta NDCs	406	938	2.31	938	2.31	105,963,363	0.38	150,219,314.8
J3490 + Granix NDCs	35	68	1.94	68	1.94	105,963,363	0.03	150,219,314.8
J3490 + Zarxio NDCs	172	323	1.88	323	1.88	105,963,363	0.16	150,219,314.8
J3490 + Remicade NDCs	56	108	1.93	108	1.93	105,963,363	0.05	150,219,314.8
J3490 + Inflectra NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3490 + Renflexis NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Neupogen NDCs	*****	*****	1.20	*****	1.20	105,963,363	0.00	150,219,314.8

Table 1. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, Overall

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
J3590 + Neulasta NDCs	*****	*****	1.50	*****	1.50	105,963,363	0.01	150,219,314.8
J3590 + Granix NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Zarxio NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Remicade NDCs	*****	*****	1.00	*****	1.00	105,963,363	0.00	150,219,314.8
J3590 + Inflectra NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Renflexis NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
Combinations, Same Day Dispensing and HCPCS								
J3490 + Neupogen NDCs	232	400	1.72	400	1.72	105,963,363	0.00	150,219,314.8
J3490 + Neulasta NDCs	184	362	1.97	362	1.97	105,963,363	0.00	150,219,314.8
J3490 + Granix NDCs	*****	*****	1.47	*****	1.47	105,963,363	0.00	150,219,314.8
J3490 + Zarxio NDCs	101	200	1.98	200	1.98	105,963,363	0.00	150,219,314.8
J3490 + Remicade NDCs	17	36	2.12	36	2.12	105,963,363	0.00	150,219,314.8
J3490 + Inflectra NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3490 + Renflexis NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Neupogen NDCs	*****	*****	1.00	*****	1.00	105,963,363	0.00	150,219,314.8
J3590 + Neulasta NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Granix NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Zarxio NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Remicade NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Inflectra NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8
J3590 + Renflexis NDCs	0	0	-	0	-	105,963,363	0.00	150,219,314.8

¹ Adjusted dispensings allow one dispensing with the same generic name per day.

² Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
Identified via Healthcare Common Procedure Coding System (HCPCS)								
Neupogen (J1440) Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	*****	*****	1.00	*****	1.00	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	*****	*****	11.00	11	11.00	47,818,224	0.00	4,045,416.0
November	*****	*****	8.00	*****	8.00	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
Neupogen (J1441) Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	*****	*****	1.00	*****	1.00	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
Neupogen (J1442) Use								
2015								
January	4,915	13,580	2.76	13,593	2.77	67,636,199	7.27	5,725,480.3
February	4,805	12,832	2.67	12,853	2.67	67,695,141	7.10	5,180,382.7
March	5,119	13,964	2.73	13,982	2.73	68,122,569	7.51	5,769,793.3
April	5,092	14,090	2.77	14,113	2.77	68,083,751	7.48	5,580,567.7
May	4,785	13,746	2.87	13,766	2.88	68,106,988	7.03	5,768,682.4
June	4,924	13,931	2.83	13,946	2.83	68,069,693	7.23	5,578,913.0
July	5,049	14,202	2.81	14,219	2.82	68,104,914	7.41	5,767,400.8
August	4,767	13,343	2.80	13,358	2.80	68,207,920	6.99	5,773,795.7
September	4,735	13,110	2.77	13,137	2.77	68,250,982	6.94	5,593,486.0
October	4,746	13,290	2.80	13,319	2.81	68,415,986	6.94	5,794,131.9
November	4,378	11,435	2.61	11,465	2.62	68,435,936	6.40	5,609,779.7
December	4,466	12,122	2.71	12,215	2.74	68,475,795	6.52	5,801,670.7
2016								
January	1,949	6,206	3.18	6,299	3.23	47,580,163	4.10	4,023,276.5
February	1,871	5,825	3.11	5,841	3.12	47,653,937	3.93	3,772,301.8
March	1,855	5,759	3.10	5,785	3.12	47,828,623	3.88	4,042,407.0
April	1,690	5,263	3.11	5,272	3.12	47,635,110	3.55	3,900,491.1
May	1,604	4,896	3.05	4,914	3.06	47,635,453	3.37	4,030,105.5
June	1,514	4,652	3.07	4,668	3.08	47,640,364	3.18	3,900,051.3
July	1,372	4,264	3.11	4,285	3.12	47,666,698	2.88	4,032,397.2
August	1,344	4,317	3.21	4,332	3.22	47,717,017	2.82	4,033,197.3
September	1,275	3,902	3.06	3,923	3.08	47,757,059	2.67	3,908,397.6
October	1,238	3,903	3.15	3,917	3.16	47,818,224	2.59	4,045,416.0
November	1,134	3,482	3.07	3,493	3.08	47,830,085	2.37	3,917,112.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	1,033	3,211	3.11	3,218	3.12	47,802,605	2.16	4,045,449.0
2017								
January	1,026	3,183	3.10	3,185	3.10	46,591,044	2.20	3,940,058.4
February	1,059	3,134	2.96	3,143	2.97	45,511,150	2.33	3,479,143.0
March	1,113	3,514	3.16	3,517	3.16	45,558,701	2.44	3,854,973.7
April	1,004	3,161	3.15	3,166	3.15	45,514,720	2.21	3,727,264.6
May	1,020	3,385	3.32	3,397	3.33	45,500,661	2.24	3,849,728.5
June	973	3,050	3.13	3,060	3.14	45,494,736	2.14	3,724,607.3
July	748	2,193	2.93	2,196	2.94	31,881,369	2.35	2,699,275.6
August	783	2,352	3.00	2,352	3.00	31,652,890	2.47	2,680,329.5
September	729	2,078	2.85	2,079	2.85	31,065,145	2.35	2,545,744.9
October	723	2,285	3.16	2,286	3.16	31,022,052	2.33	2,627,309.8
November	*****	*****	2.95	*****	2.95	12,479,435	1.32	1,024,760.4
December	*****	*****	2.67	*****	2.67	5,077,319	0.18	411,832.2
2018								
January	*****	*****	4.00	*****	4.00	702,371	0.14	59,600.0
Neulasta (J2505) Use								
2015								
January	17,356	21,535	1.24	21,561	1.24	67,636,199	25.66	5,725,480.3
February	16,511	19,341	1.17	19,361	1.17	67,695,141	24.39	5,180,382.7
March	17,365	21,098	1.21	21,124	1.22	68,122,569	25.49	5,769,793.3
April	17,476	21,695	1.24	21,724	1.24	68,083,751	25.67	5,580,567.7
May	17,183	21,144	1.23	21,170	1.23	68,106,988	25.23	5,768,682.4
June	17,175	20,825	1.21	20,844	1.21	68,069,693	25.23	5,578,913.0
July	17,740	22,611	1.27	22,630	1.28	68,104,914	26.05	5,767,400.8
August	17,095	20,616	1.21	20,634	1.21	68,207,920	25.06	5,773,795.7
September	17,199	20,979	1.22	20,997	1.22	68,250,982	25.20	5,593,486.0
October	17,629	22,385	1.27	22,402	1.27	68,415,986	25.77	5,794,131.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	16,395	19,187	1.17	19,206	1.17	68,435,936	23.96	5,609,779.7
December	17,188	22,361	1.30	22,385	1.30	68,475,795	25.10	5,801,670.7
2016								
January	7,871	10,019	1.27	10,036	1.28	47,580,163	16.54	4,023,276.5
February	7,960	10,103	1.27	10,114	1.27	47,653,937	16.70	3,772,301.8
March	8,325	11,293	1.36	11,307	1.36	47,828,623	17.41	4,042,407.0
April	8,159	10,711	1.31	10,722	1.31	47,635,110	17.13	3,900,491.1
May	8,134	10,448	1.28	10,458	1.29	47,635,453	17.08	4,030,105.5
June	8,247	11,107	1.35	11,120	1.35	47,640,364	17.31	3,900,051.3
July	8,055	10,494	1.30	10,509	1.30	47,666,698	16.90	4,032,397.2
August	8,256	11,053	1.34	11,065	1.34	47,717,017	17.30	4,033,197.3
September	8,063	10,786	1.34	10,797	1.34	47,757,059	16.88	3,908,397.6
October	7,825	9,994	1.28	10,002	1.28	47,818,224	16.36	4,045,416.0
November	7,671	9,931	1.29	9,941	1.30	47,830,085	16.04	3,917,112.2
December	7,617	10,513	1.38	10,526	1.38	47,802,605	15.93	4,045,449.0
2017								
January	7,190	9,232	1.28	9,249	1.29	46,591,044	15.43	3,940,058.4
February	6,996	8,833	1.26	8,841	1.26	45,511,150	15.37	3,479,143.0
March	7,501	10,368	1.38	10,378	1.38	45,558,701	16.46	3,854,973.7
April	7,027	8,938	1.27	8,948	1.27	45,514,720	15.44	3,727,264.6
May	7,205	9,555	1.33	9,571	1.33	45,500,661	15.83	3,849,728.5
June	7,310	9,956	1.36	9,971	1.36	45,494,736	16.07	3,724,607.3
July	5,708	7,223	1.27	7,225	1.27	31,881,369	17.90	2,699,275.6
August	5,845	7,861	1.34	7,861	1.34	31,652,890	18.47	2,680,329.5
September	5,631	7,301	1.30	7,305	1.30	31,065,145	18.13	2,545,744.9
October	5,529	7,148	1.29	7,151	1.29	31,022,052	17.82	2,627,309.8
November	1,296	1,758	1.36	1,758	1.36	12,479,435	10.39	1,024,760.4
December	40	47	1.18	47	1.18	5,077,319	0.79	411,832.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
2018								
January	23	33	1.43	33	1.43	702,371	3.27	59,600.0
Granix (J1446) Use								
2015								
January	1,061	2,495	2.35	2,499	2.36	67,636,199	1.57	5,725,480.3
February	*****	*****	2.41	*****	2.42	67,695,141	1.56	5,180,382.7
March	1,171	2,975	2.54	2,981	2.55	68,122,569	1.72	5,769,793.3
April	1,259	3,150	2.50	3,155	2.51	68,083,751	1.85	5,580,567.7
May	1,334	3,346	2.51	3,347	2.51	68,106,988	1.96	5,768,682.4
June	1,366	3,514	2.57	3,515	2.57	68,069,693	2.01	5,578,913.0
July	1,440	3,583	2.49	3,585	2.49	68,104,914	2.11	5,767,400.8
August	1,434	3,356	2.34	3,356	2.34	68,207,920	2.10	5,773,795.7
September	1,381	3,437	2.49	3,441	2.49	68,250,982	2.02	5,593,486.0
October	1,455	3,588	2.47	3,590	2.47	68,415,986	2.13	5,794,131.9
November	1,397	3,526	2.52	3,532	2.53	68,435,936	2.04	5,609,779.7
December	1,475	3,541	2.40	3,543	2.40	68,475,795	2.15	5,801,670.7
2016								
January	*****	*****	2.00	*****	2.00	47,580,163	0.00	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.00	3,772,301.8
March	*****	*****	1.00	*****	1.00	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
Granix (J1447) Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	*****	*****	1.00	*****	1.00	68,435,936	0.00	5,609,779.7
December	*****	*****	1.17	*****	1.17	68,475,795	0.01	5,801,670.7
2016								
January	509	1,616	3.17	1,616	3.17	47,580,163	1.07	4,023,276.5
February	514	1,631	3.17	1,637	3.18	47,653,937	1.08	3,772,301.8
March	572	1,843	3.22	1,849	3.23	47,828,623	1.20	4,042,407.0
April	547	1,809	3.31	1,810	3.31	47,635,110	1.15	3,900,491.1
May	530	1,761	3.32	1,770	3.34	47,635,453	1.11	4,030,105.5
June	549	1,871	3.41	1,871	3.41	47,640,364	1.15	3,900,051.3
July	552	1,916	3.47	1,917	3.47	47,666,698	1.16	4,032,397.2
August	561	2,063	3.68	2,064	3.68	47,717,017	1.18	4,033,197.3
September	538	1,955	3.63	1,955	3.63	47,757,059	1.13	3,908,397.6
October	518	1,802	3.48	1,806	3.49	47,818,224	1.08	4,045,416.0
November	454	1,624	3.58	1,625	3.58	47,830,085	0.95	3,917,112.2
December	438	1,477	3.37	1,477	3.37	47,802,605	0.92	4,045,449.0
2017								
January	464	1,590	3.43	1,590	3.43	46,591,044	1.00	3,940,058.4
February	458	1,491	3.26	1,493	3.26	45,511,150	1.01	3,479,143.0
March	478	1,657	3.47	1,661	3.47	45,558,701	1.05	3,854,973.7
April	449	1,579	3.52	1,582	3.52	45,514,720	0.99	3,727,264.6
May	494	1,672	3.38	1,673	3.39	45,500,661	1.09	3,849,728.5
June	485	1,707	3.52	1,708	3.52	45,494,736	1.07	3,724,607.3
July	382	1,249	3.27	1,250	3.27	31,881,369	1.20	2,699,275.6
August	439	1,493	3.40	1,494	3.40	31,652,890	1.39	2,680,329.5
September	413	1,283	3.11	1,283	3.11	31,065,145	1.33	2,545,744.9
October	393	1,283	3.26	1,284	3.27	31,022,052	1.27	2,627,309.8
November	125	410	3.28	410	3.28	12,479,435	1.00	1,024,760.4
December	51	236	4.63	236	4.63	5,077,319	1.00	411,832.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
2018								
January	*****	*****	4.81	*****	4.83	702,371	6.69	59,600.0
Zarxio (Q5101) Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	*****	*****	7.00	*****	7.00	68,104,914	0.00	5,767,400.8
August	*****	*****	3.86	*****	3.86	68,207,920	0.01	5,773,795.7
September	*****	*****	2.45	*****	2.45	68,250,982	0.03	5,593,486.0
October	54	145	2.69	145	2.69	68,415,986	0.08	5,794,131.9
November	65	172	2.65	173	2.66	68,435,936	0.09	5,609,779.7
December	133	374	2.81	374	2.81	68,475,795	0.19	5,801,670.7
2016								
January	227	758	3.34	758	3.34	47,580,163	0.48	4,023,276.5
February	326	1,313	4.03	1,313	4.03	47,653,937	0.68	3,772,301.8
March	523	1,918	3.67	1,920	3.67	47,828,623	1.09	4,042,407.0
April	640	2,337	3.65	2,345	3.66	47,635,110	1.34	3,900,491.1
May	708	2,729	3.85	2,744	3.88	47,635,453	1.49	4,030,105.5
June	789	3,044	3.86	3,056	3.87	47,640,364	1.66	3,900,051.3
July	858	3,187	3.71	3,201	3.73	47,666,698	1.80	4,032,397.2
August	939	3,560	3.79	3,573	3.81	47,717,017	1.97	4,033,197.3
September	962	3,608	3.75	3,617	3.76	47,757,059	2.01	3,908,397.6
October	1,013	3,725	3.68	3,726	3.68	47,818,224	2.12	4,045,416.0
November	979	3,410	3.48	3,413	3.49	47,830,085	2.05	3,917,112.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December 2017	956	3,465	3.62	3,466	3.63	47,802,605	2.00	4,045,449.0
January	1,022	3,647	3.57	3,648	3.57	46,591,044	2.19	3,940,058.4
February	1,055	3,733	3.54	3,736	3.54	45,511,150	2.32	3,479,143.0
March	1,198	4,390	3.66	4,396	3.67	45,558,701	2.63	3,854,973.7
April	1,088	3,894	3.58	3,898	3.58	45,514,720	2.39	3,727,264.6
May	1,197	4,464	3.73	4,470	3.73	45,500,661	2.63	3,849,728.5
June	1,200	4,348	3.62	4,353	3.63	45,494,736	2.64	3,724,607.3
July	1,047	3,767	3.60	3,780	3.61	31,881,369	3.28	2,699,275.6
August	1,118	4,019	3.59	4,029	3.60	31,652,890	3.53	2,680,329.5
September	1,000	3,479	3.48	3,485	3.49	31,065,145	3.22	2,545,744.9
October	1,082	3,991	3.69	3,993	3.69	31,022,052	3.49	2,627,309.8
November	445	1,839	4.13	1,840	4.13	12,479,435	3.57	1,024,760.4
December 2018	285	1,356	4.76	1,360	4.77	5,077,319	5.61	411,832.2
January 2018	35	143	4.09	143	4.09	702,371	4.98	59,600.0
Remicade (J1745) Use								
2015								
January	22,795	23,210	1.02	23,247	1.02	67,636,199	33.70	5,725,480.3
February	20,558	20,859	1.01	20,897	1.02	67,695,141	30.37	5,180,382.7
March	23,851	24,397	1.02	24,446	1.02	68,122,569	35.01	5,769,793.3
April	23,662	24,298	1.03	24,333	1.03	68,083,751	34.75	5,580,567.7
May	22,412	22,931	1.02	22,961	1.02	68,106,988	32.91	5,768,682.4
June	23,903	24,504	1.03	24,553	1.03	68,069,693	35.12	5,578,913.0
July	24,489	25,102	1.03	25,139	1.03	68,104,914	35.96	5,767,400.8
August	22,794	23,260	1.02	23,305	1.02	68,207,920	33.42	5,773,795.7
September	23,554	24,130	1.02	24,164	1.03	68,250,982	34.51	5,593,486.0
October	23,793	24,416	1.03	24,468	1.03	68,415,986	34.78	5,794,131.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	21,780	22,219	1.02	22,262	1.02	68,435,936	31.83	5,609,779.7
December	24,909	25,606	1.03	25,652	1.03	68,475,795	36.38	5,801,670.7
2016								
January	13,553	13,778	1.02	13,816	1.02	47,580,163	28.48	4,023,276.5
February	13,686	14,048	1.03	14,084	1.03	47,653,937	28.72	3,772,301.8
March	15,389	15,928	1.04	15,971	1.04	47,828,623	32.18	4,042,407.0
April	14,173	14,555	1.03	14,587	1.03	47,635,110	29.75	3,900,491.1
May	14,534	14,994	1.03	15,038	1.03	47,635,453	30.51	4,030,105.5
June	15,197	15,730	1.04	15,785	1.04	47,640,364	31.90	3,900,051.3
July	14,473	14,820	1.02	14,865	1.03	47,666,698	30.36	4,032,397.2
August	15,631	16,158	1.03	16,216	1.04	47,717,017	32.76	4,033,197.3
September	15,019	15,453	1.03	15,492	1.03	47,757,059	31.45	3,908,397.6
October	14,345	14,667	1.02	14,705	1.03	47,818,224	30.00	4,045,416.0
November	14,886	15,310	1.03	15,347	1.03	47,830,085	31.12	3,917,112.2
December	14,957	15,445	1.03	15,489	1.04	47,802,605	31.29	4,045,449.0
2017								
January	14,231	14,501	1.02	14,541	1.02	46,591,044	30.54	3,940,058.4
February	12,650	12,921	1.02	12,966	1.02	45,511,150	27.80	3,479,143.0
March	14,916	15,457	1.04	15,504	1.04	45,558,701	32.74	3,854,973.7
April	13,148	13,428	1.02	13,471	1.02	45,514,720	28.89	3,727,264.6
May	14,392	14,893	1.03	14,936	1.04	45,500,661	31.63	3,849,728.5
June	14,388	14,825	1.03	14,870	1.03	45,494,736	31.63	3,724,607.3
July	9,286	9,477	1.02	9,488	1.02	31,881,369	29.13	2,699,275.6
August	9,994	10,311	1.03	10,327	1.03	31,652,890	31.57	2,680,329.5
September	9,348	9,546	1.02	9,559	1.02	31,065,145	30.09	2,545,744.9
October	9,381	9,658	1.03	9,672	1.03	31,022,052	30.24	2,627,309.8
November	2,914	3,004	1.03	3,011	1.03	12,479,435	23.35	1,024,760.4
December	342	343	1.00	348	1.02	5,077,319	6.74	411,832.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
2018								
January	315	318	1.01	327	1.04	702,371	44.85	59,600.0
Infliximab (Q5102) Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	*****	*****	1.00	*****	1.00	47,640,364	0.00	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.02	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.00	4,033,197.3
September	*****	*****	1.00	*****	1.00	47,757,059	0.01	3,908,397.6
October	*****	*****	1.00	*****	1.00	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.00	3,940,058.4
February	*****	*****	1.00	*****	1.00	45,511,150	0.01	3,479,143.0
March	33	33	1.00	33	1.00	45,558,701	0.07	3,854,973.7
April	47	49	1.04	49	1.04	45,514,720	0.10	3,727,264.6
May	212	220	1.04	221	1.04	45,500,661	0.47	3,849,728.5
June	324	342	1.06	347	1.07	45,494,736	0.71	3,724,607.3
July	344	361	1.05	368	1.07	31,881,369	1.08	2,699,275.6
August	366	390	1.07	392	1.07	31,652,890	1.16	2,680,329.5
September	388	404	1.04	407	1.05	31,065,145	1.25	2,545,744.9
October	398	415	1.04	417	1.05	31,022,052	1.28	2,627,309.8
November	250	258	1.03	265	1.06	12,479,435	2.00	1,024,760.4
December	120	123	1.03	128	1.07	5,077,319	2.36	411,832.2
2018								
January	97	101	1.04	104	1.07	702,371	13.81	59,600.0
Identified via National Drug Codes (NDCs)								
Neupogen dispensings Use								
2015								
January	2,158	2,595	1.20	2,595	1.20	67,636,199	3.19	5,725,480.3
February	2,165	2,538	1.17	2,538	1.17	67,695,141	3.20	5,180,382.7
March	2,383	2,880	1.21	2,880	1.21	68,122,569	3.50	5,769,793.3
April	2,337	2,854	1.22	2,854	1.22	68,083,751	3.43	5,580,567.7
May	2,407	2,890	1.20	2,890	1.20	68,106,988	3.53	5,768,682.4
June	2,415	2,959	1.23	2,959	1.23	68,069,693	3.55	5,578,913.0
July	2,474	3,083	1.25	3,083	1.25	68,104,914	3.63	5,767,400.8
August	2,467	2,991	1.21	2,991	1.21	68,207,920	3.62	5,773,795.7
September	2,494	3,058	1.23	3,058	1.23	68,250,982	3.65	5,593,486.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	2,601	3,205	1.23	3,205	1.23	68,415,986	3.80	5,794,131.9
November	2,338	2,778	1.19	2,778	1.19	68,435,936	3.42	5,609,779.7
December	2,451	3,116	1.27	3,116	1.27	68,475,795	3.58	5,801,670.7
2016								
January	978	1,124	1.15	1,124	1.15	47,580,163	2.06	4,023,276.5
February	797	898	1.13	898	1.13	47,653,937	1.67	3,772,301.8
March	772	931	1.21	931	1.21	47,828,623	1.61	4,042,407.0
April	704	802	1.14	802	1.14	47,635,110	1.48	3,900,491.1
May	681	787	1.16	787	1.16	47,635,453	1.43	4,030,105.5
June	639	743	1.16	743	1.16	47,640,364	1.34	3,900,051.3
July	628	698	1.11	698	1.11	47,666,698	1.32	4,032,397.2
August	666	765	1.15	765	1.15	47,717,017	1.40	4,033,197.3
September	692	797	1.15	797	1.15	47,757,059	1.45	3,908,397.6
October	649	738	1.14	738	1.14	47,818,224	1.36	4,045,416.0
November	648	769	1.19	769	1.19	47,830,085	1.35	3,917,112.2
December	653	757	1.16	757	1.16	47,802,605	1.37	4,045,449.0
2017								
January	445	508	1.14	508	1.14	46,591,044	0.96	3,940,058.4
February	385	425	1.10	425	1.10	45,511,150	0.85	3,479,143.0
March	448	527	1.18	527	1.18	45,558,701	0.98	3,854,973.7
April	441	510	1.16	510	1.16	45,514,720	0.97	3,727,264.6
May	436	528	1.21	528	1.21	45,500,661	0.96	3,849,728.5
June	430	527	1.23	527	1.23	45,494,736	0.95	3,724,607.3
July	329	383	1.16	383	1.16	31,881,369	1.03	2,699,275.6
August	353	430	1.22	430	1.22	31,652,890	1.12	2,680,329.5
September	322	366	1.14	366	1.14	31,065,145	1.04	2,545,744.9
October	332	385	1.16	385	1.16	31,022,052	1.07	2,627,309.8
November	112	133	1.19	133	1.19	12,479,435	0.90	1,024,760.4

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	28	36	1.29	36	1.29	5,077,319	0.55	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
Neulasta dispensings Use								
2015								
January	1,072	1,218	1.14	1,218	1.14	67,636,199	1.58	5,725,480.3
February	1,035	1,150	1.11	1,150	1.11	67,695,141	1.53	5,180,382.7
March	1,148	1,343	1.17	1,343	1.17	68,122,569	1.69	5,769,793.3
April	1,140	1,333	1.17	1,333	1.17	68,083,751	1.67	5,580,567.7
May	1,141	1,324	1.16	1,324	1.16	68,106,988	1.68	5,768,682.4
June	1,151	1,391	1.21	1,391	1.21	68,069,693	1.69	5,578,913.0
July	1,145	1,362	1.19	1,362	1.19	68,104,914	1.68	5,767,400.8
August	1,165	1,355	1.16	1,355	1.16	68,207,920	1.71	5,773,795.7
September	1,155	1,374	1.19	1,374	1.19	68,250,982	1.69	5,593,486.0
October	1,150	1,391	1.21	1,391	1.21	68,415,986	1.68	5,794,131.9
November	1,113	1,288	1.16	1,288	1.16	68,435,936	1.63	5,609,779.7
December	1,145	1,439	1.26	1,439	1.26	68,475,795	1.67	5,801,670.7
2016								
January	565	671	1.19	671	1.19	47,580,163	1.19	4,023,276.5
February	591	683	1.16	683	1.16	47,653,937	1.24	3,772,301.8
March	638	792	1.24	792	1.24	47,828,623	1.33	4,042,407.0
April	571	672	1.18	672	1.18	47,635,110	1.20	3,900,491.1
May	591	715	1.21	715	1.21	47,635,453	1.24	4,030,105.5
June	604	730	1.21	730	1.21	47,640,364	1.27	3,900,051.3
July	611	712	1.17	712	1.17	47,666,698	1.28	4,032,397.2
August	581	709	1.22	709	1.22	47,717,017	1.22	4,033,197.3
September	530	635	1.20	635	1.20	47,757,059	1.11	3,908,397.6
October	524	623	1.19	623	1.19	47,818,224	1.10	4,045,416.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	541	672	1.24	672	1.24	47,830,085	1.13	3,917,112.2
December	534	649	1.22	649	1.22	47,802,605	1.12	4,045,449.0
2017								
January	491	574	1.17	574	1.17	46,591,044	1.05	3,940,058.4
February	496	577	1.16	577	1.16	45,511,150	1.09	3,479,143.0
March	530	651	1.23	651	1.23	45,558,701	1.16	3,854,973.7
April	502	572	1.14	572	1.14	45,514,720	1.10	3,727,264.6
May	528	648	1.23	648	1.23	45,500,661	1.16	3,849,728.5
June	511	624	1.22	624	1.22	45,494,736	1.12	3,724,607.3
July	291	338	1.16	338	1.16	31,881,369	0.91	2,699,275.6
August	294	370	1.26	370	1.26	31,652,890	0.93	2,680,329.5
September	265	311	1.17	311	1.17	31,065,145	0.85	2,545,744.9
October	289	353	1.22	353	1.22	31,022,052	0.93	2,627,309.8
November	*****	*****	1.13	*****	1.13	12,479,435	0.58	1,024,760.4
December	*****	*****	1.00	*****	1.00	5,077,319	0.12	411,832.2
2018								
January	0	0	.	0		702,371	0.00	59,600.0
Granix dispensings Use								
2015								
January	23	25	1.09	25	1.09	67,636,199	0.03	5,725,480.3
February	25	28	1.12	28	1.12	67,695,141	0.04	5,180,382.7
March	34	40	1.18	40	1.18	68,122,569	0.05	5,769,793.3
April	35	38	1.09	38	1.09	68,083,751	0.05	5,580,567.7
May	41	45	1.10	45	1.10	68,106,988	0.06	5,768,682.4
June	53	64	1.21	64	1.21	68,069,693	0.08	5,578,913.0
July	59	69	1.17	69	1.17	68,104,914	0.09	5,767,400.8
August	53	72	1.36	72	1.36	68,207,920	0.08	5,773,795.7
September	65	84	1.29	84	1.29	68,250,982	0.10	5,593,486.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	55	65	1.18	65	1.18	68,415,986	0.08	5,794,131.9
November	55	59	1.07	59	1.07	68,435,936	0.08	5,609,779.7
December	59	71	1.20	71	1.20	68,475,795	0.09	5,801,670.7
2016								
January	21	25	1.19	25	1.19	47,580,163	0.04	4,023,276.5
February	24	29	1.21	29	1.21	47,653,937	0.05	3,772,301.8
March	20	25	1.25	25	1.25	47,828,623	0.04	4,042,407.0
April	17	23	1.35	23	1.35	47,635,110	0.04	3,900,491.1
May	21	23	1.10	23	1.10	47,635,453	0.04	4,030,105.5
June	27	30	1.11	30	1.11	47,640,364	0.06	3,900,051.3
July	39	41	1.05	41	1.05	47,666,698	0.08	4,032,397.2
August	40	47	1.18	47	1.18	47,717,017	0.08	4,033,197.3
September	36	43	1.19	43	1.19	47,757,059	0.08	3,908,397.6
October	36	39	1.08	39	1.08	47,818,224	0.08	4,045,416.0
November	45	52	1.16	52	1.16	47,830,085	0.09	3,917,112.2
December	45	53	1.18	53	1.18	47,802,605	0.09	4,045,449.0
2017								
January	58	66	1.14	66	1.14	46,591,044	0.12	3,940,058.4
February	59	70	1.19	70	1.19	45,511,150	0.13	3,479,143.0
March	64	81	1.27	81	1.27	45,558,701	0.14	3,854,973.7
April	55	61	1.11	61	1.11	45,514,720	0.12	3,727,264.6
May	59	70	1.19	70	1.19	45,500,661	0.13	3,849,728.5
June	59	72	1.22	72	1.22	45,494,736	0.13	3,724,607.3
July	46	51	1.11	51	1.11	31,881,369	0.14	2,699,275.6
August	50	64	1.28	64	1.28	31,652,890	0.16	2,680,329.5
September	54	65	1.20	65	1.20	31,065,145	0.17	2,545,744.9
October	44	52	1.18	52	1.18	31,022,052	0.14	2,627,309.8
November	*****	*****	1.24	*****	1.24	12,479,435	0.20	1,024,760.4

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	*****	*****	1.50	*****	1.50	5,077,319	0.08	411,832.2
2018								
January	*****	*****	1.50	*****	1.50	702,371	0.28	59,600.0
Zarxio dispensings Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	*****	*****	1.00	*****	1.00	68,250,982	0.01	5,593,486.0
October	*****	*****	1.00	*****	1.00	68,415,986	0.01	5,794,131.9
November	*****	*****	1.00	*****	1.00	68,435,936	0.01	5,609,779.7
December	12	14	1.17	14	1.17	68,475,795	0.02	5,801,670.7
2016								
January	399	472	1.18	472	1.18	47,580,163	0.84	4,023,276.5
February	614	784	1.28	784	1.28	47,653,937	1.29	3,772,301.8
March	730	986	1.35	986	1.35	47,828,623	1.53	4,042,407.0
April	752	980	1.30	980	1.30	47,635,110	1.58	3,900,491.1
May	820	1,076	1.31	1,076	1.31	47,635,453	1.72	4,030,105.5
June	830	1,114	1.34	1,114	1.34	47,640,364	1.74	3,900,051.3
July	847	1,097	1.30	1,097	1.30	47,666,698	1.78	4,032,397.2
August	904	1,256	1.39	1,256	1.39	47,717,017	1.89	4,033,197.3
September	934	1,259	1.35	1,259	1.35	47,757,059	1.96	3,908,397.6
October	933	1,239	1.33	1,239	1.33	47,818,224	1.95	4,045,416.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	954	1,229	1.29	1,229	1.29	47,830,085	1.99	3,917,112.2
December	936	1,259	1.35	1,259	1.35	47,802,605	1.96	4,045,449.0
2017								
January	1,006	1,293	1.29	1,293	1.29	46,591,044	2.16	3,940,058.4
February	1,014	1,260	1.24	1,260	1.24	45,511,150	2.23	3,479,143.0
March	1,116	1,473	1.32	1,473	1.32	45,558,701	2.45	3,854,973.7
April	1,090	1,379	1.27	1,379	1.27	45,514,720	2.39	3,727,264.6
May	1,116	1,464	1.31	1,464	1.31	45,500,661	2.45	3,849,728.5
June	1,192	1,550	1.30	1,550	1.30	45,494,736	2.62	3,724,607.3
July	1,047	1,356	1.30	1,356	1.30	31,881,369	3.28	2,699,275.6
August	1,027	1,407	1.37	1,407	1.37	31,652,890	3.24	2,680,329.5
September	890	1,107	1.24	1,107	1.24	31,065,145	2.86	2,545,744.9
October	770	966	1.25	966	1.25	31,022,052	2.48	2,627,309.8
November	638	850	1.33	850	1.33	12,479,435	5.11	1,024,760.4
December	601	777	1.29	777	1.29	5,077,319	11.84	411,832.2
2018								
January	44	58	1.32	58	1.32	702,371	6.26	59,600.0
Remicade dispensings Use								
2015								
January	1,362	1,378	1.01	1,378	1.01	67,636,199	2.01	5,725,480.3
February	1,248	1,262	1.01	1,262	1.01	67,695,141	1.84	5,180,382.7
March	1,497	1,516	1.01	1,516	1.01	68,122,569	2.20	5,769,793.3
April	1,427	1,458	1.02	1,458	1.02	68,083,751	2.10	5,580,567.7
May	1,406	1,424	1.01	1,424	1.01	68,106,988	2.06	5,768,682.4
June	1,458	1,473	1.01	1,473	1.01	68,069,693	2.14	5,578,913.0
July	1,540	1,570	1.02	1,570	1.02	68,104,914	2.26	5,767,400.8
August	1,452	1,482	1.02	1,482	1.02	68,207,920	2.13	5,773,795.7
September	1,497	1,520	1.02	1,520	1.02	68,250,982	2.19	5,593,486.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	1,585	1,611	1.02	1,611	1.02	68,415,986	2.32	5,794,131.9
November	1,492	1,507	1.01	1,507	1.01	68,435,936	2.18	5,609,779.7
December	1,640	1,683	1.03	1,683	1.03	68,475,795	2.40	5,801,670.7
2016								
January	985	995	1.01	995	1.01	47,580,163	2.07	4,023,276.5
February	990	995	1.01	995	1.01	47,653,937	2.08	3,772,301.8
March	1,117	1,139	1.02	1,139	1.02	47,828,623	2.34	4,042,407.0
April	1,008	1,011	1.00	1,011	1.00	47,635,110	2.12	3,900,491.1
May	1,080	1,094	1.01	1,094	1.01	47,635,453	2.27	4,030,105.5
June	1,048	1,064	1.02	1,064	1.02	47,640,364	2.20	3,900,051.3
July	974	987	1.01	987	1.01	47,666,698	2.04	4,032,397.2
August	1,128	1,148	1.02	1,148	1.02	47,717,017	2.36	4,033,197.3
September	1,041	1,053	1.01	1,053	1.01	47,757,059	2.18	3,908,397.6
October	1,064	1,076	1.01	1,076	1.01	47,818,224	2.23	4,045,416.0
November	1,063	1,085	1.02	1,085	1.02	47,830,085	2.22	3,917,112.2
December	1,103	1,121	1.02	1,121	1.02	47,802,605	2.31	4,045,449.0
2017								
January	1,002	1,018	1.02	1,018	1.02	46,591,044	2.15	3,940,058.4
February	911	926	1.02	926	1.02	45,511,150	2.00	3,479,143.0
March	1,100	1,121	1.02	1,121	1.02	45,558,701	2.41	3,854,973.7
April	973	981	1.01	981	1.01	45,514,720	2.14	3,727,264.6
May	1,103	1,125	1.02	1,125	1.02	45,500,661	2.42	3,849,728.5
June	977	990	1.01	990	1.01	45,494,736	2.15	3,724,607.3
July	736	742	1.01	742	1.01	31,881,369	2.31	2,699,275.6
August	744	757	1.02	757	1.02	31,652,890	2.35	2,680,329.5
September	622	628	1.01	628	1.01	31,065,145	2.00	2,545,744.9
October	606	616	1.02	616	1.02	31,022,052	1.95	2,627,309.8
November	*****	*****	1.00	*****	1.00	12,479,435	1.75	1,024,760.4

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December	*****	*****	1.00	*****	1.00	5,077,319	0.02	411,832.2
2018								
January	*****	*****	1.00	*****	1.00	702,371	0.14	59,600.0
Inflectra dispensings Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	*****	*****	1.05	*****	1.05	45,500,661	0.09	3,849,728.5
June	91	97	1.07	97	1.07	45,494,736	0.20	3,724,607.3
July	88	92	1.05	92	1.05	31,881,369	0.28	2,699,275.6
August	80	85	1.06	85	1.06	31,652,890	0.25	2,680,329.5
September	*****	*****	1.00	*****	1.00	31,065,145	0.01	2,545,744.9
October	*****	*****	1.00	*****	1.00	31,022,052	0.01	2,627,309.8
November	*****	*****	1.00	*****	1.00	12,479,435	0.01	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
Renflexis dispensings Use								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	.	0	-	47,580,163	0.00	4,023,276.5
February	0	0	.	0	-	47,653,937	0.00	3,772,301.8
March	0	0	.	0	-	47,828,623	0.00	4,042,407.0
April	0	0	.	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
December 2018	0	0	-	0	-	5,077,319	0.00	411,832.2
January 2018	0	0	-	0	-	702,371	0.00	59,600.0
Combinations, HCPCS Occurring Within -3 through +3 days of a Dispensing								
J3490 + Neupogen NDCs								
2015								
January	34	39	1.15	39	1.15	67,636,199	0.05	5,725,480.3
February	35	42	1.20	42	1.20	67,695,141	0.05	5,180,382.7
March	49	65	1.33	65	1.33	68,122,569	0.07	5,769,793.3
April	44	57	1.30	57	1.30	68,083,751	0.06	5,580,567.7
May	52	64	1.23	64	1.23	68,106,988	0.08	5,768,682.4
June	40	51	1.28	51	1.28	68,069,693	0.06	5,578,913.0
July	41	51	1.24	51	1.24	68,104,914	0.06	5,767,400.8
August	40	48	1.20	48	1.20	68,207,920	0.06	5,773,795.7
September	34	39	1.15	39	1.15	68,250,982	0.05	5,593,486.0
October	47	57	1.21	57	1.21	68,415,986	0.07	5,794,131.9
November	28	29	1.04	29	1.04	68,435,936	0.04	5,609,779.7
December	33	41	1.24	41	1.24	68,475,795	0.05	5,801,670.7
2016								
January	15	17	1.13	17	1.13	47,580,163	0.03	4,023,276.5
February	15	20	1.33	20	1.33	47,653,937	0.03	3,772,301.8
March	20	27	1.35	27	1.35	47,828,623	0.04	4,042,407.0
April	17	21	1.24	21	1.24	47,635,110	0.04	3,900,491.1
May	14	20	1.43	20	1.43	47,635,453	0.03	4,030,105.5
June	18	19	1.06	19	1.06	47,640,364	0.04	3,900,051.3
July	16	20	1.25	20	1.25	47,666,698	0.03	4,032,397.2
August	17	20	1.18	20	1.18	47,717,017	0.04	4,033,197.3
September	15	19	1.27	19	1.27	47,757,059	0.03	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	14	16	1.14	16	1.14	47,818,224	0.03	4,045,416.0
November	14	17	1.21	17	1.21	47,830,085	0.03	3,917,112.2
December	20	26	1.30	26	1.30	47,802,605	0.04	4,045,449.0
2017								
January	19	24	1.26	24	1.26	46,591,044	0.04	3,940,058.4
February	*****	*****	1.14	*****	1.14	45,511,150	0.02	3,479,143.0
March	*****	*****	1.71	*****	1.71	45,558,701	0.02	3,854,973.7
April	*****	*****	1.17	*****	1.17	45,514,720	0.01	3,727,264.6
May	11	15	1.36	15	1.36	45,500,661	0.02	3,849,728.5
June	*****	*****	1.00	*****	1.00	45,494,736	0.02	3,724,607.3
July	*****	*****	1.10	*****	1.10	31,881,369	0.03	2,699,275.6
August	*****	*****	1.25	*****	1.25	31,652,890	0.03	2,680,329.5
September	*****	*****	1.00	*****	1.00	31,065,145	0.01	2,545,744.9
October	*****	*****	1.43	*****	1.43	31,022,052	0.02	2,627,309.8
November	*****	*****	2.00	*****	2.00	12,479,435	0.02	1,024,760.4
December	*****	*****	2.00	*****	2.00	5,077,319	0.02	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Neulasta NDCs								
2015								
January	13	16	1.23	16	1.23	67,636,199	0.02	5,725,480.3
February	29	32	1.10	32	1.10	67,695,141	0.04	5,180,382.7
March	37	42	1.14	42	1.14	68,122,569	0.05	5,769,793.3
April	21	27	1.29	27	1.29	68,083,751	0.03	5,580,567.7
May	23	30	1.30	30	1.30	68,106,988	0.03	5,768,682.4
June	27	32	1.19	32	1.19	68,069,693	0.04	5,578,913.0
July	33	41	1.24	41	1.24	68,104,914	0.05	5,767,400.8
August	37	42	1.14	42	1.14	68,207,920	0.05	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	31	39	1.26	39	1.26	68,250,982	0.05	5,593,486.0
October	24	33	1.38	33	1.38	68,415,986	0.04	5,794,131.9
November	18	24	1.33	24	1.33	68,435,936	0.03	5,609,779.7
December	20	24	1.20	24	1.20	68,475,795	0.03	5,801,670.7
2016								
January	19	22	1.16	22	1.16	47,580,163	0.04	4,023,276.5
February	16	20	1.25	20	1.25	47,653,937	0.03	3,772,301.8
March	22	28	1.27	28	1.27	47,828,623	0.05	4,042,407.0
April	22	30	1.36	30	1.36	47,635,110	0.05	3,900,491.1
May	18	26	1.44	26	1.44	47,635,453	0.04	4,030,105.5
June	28	38	1.36	38	1.36	47,640,364	0.06	3,900,051.3
July	21	30	1.43	30	1.43	47,666,698	0.04	4,032,397.2
August	15	28	1.87	28	1.87	47,717,017	0.03	4,033,197.3
September	16	28	1.75	28	1.75	47,757,059	0.03	3,908,397.6
October	17	22	1.29	22	1.29	47,818,224	0.04	4,045,416.0
November	19	26	1.37	26	1.37	47,830,085	0.04	3,917,112.2
December	19	22	1.16	22	1.16	47,802,605	0.04	4,045,449.0
2017								
January	20	25	1.25	25	1.25	46,591,044	0.04	3,940,058.4
February	17	22	1.29	22	1.29	45,511,150	0.04	3,479,143.0
March	21	25	1.19	25	1.19	45,558,701	0.05	3,854,973.7
April	22	26	1.18	26	1.18	45,514,720	0.05	3,727,264.6
May	18	26	1.44	26	1.44	45,500,661	0.04	3,849,728.5
June	21	32	1.52	32	1.52	45,494,736	0.05	3,724,607.3
July	13	14	1.08	14	1.08	31,881,369	0.04	2,699,275.6
August	19	22	1.16	22	1.16	31,652,890	0.06	2,680,329.5
September	*****	*****	1.36	*****	1.36	31,065,145	0.04	2,545,744.9
October	16	23	1.44	23	1.44	31,022,052	0.05	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	*****	*****	1.50	*****	1.50	12,479,435	0.03	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Granix NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	*****	*****	1.50	*****	1.50	67,695,141	0.00	5,180,382.7
March	*****	*****	1.00	*****	1.00	68,122,569	0.00	5,769,793.3
April	*****	*****	1.00	*****	1.00	68,083,751	0.00	5,580,567.7
May	*****	*****	1.00	*****	1.00	68,106,988	0.00	5,768,682.4
June	0	0	.	0	.	68,069,693	0.00	5,578,913.0
July	*****	*****	1.00	*****	1.00	68,104,914	0.00	5,767,400.8
August	*****	*****	2.00	*****	2.00	68,207,920	0.00	5,773,795.7
September	*****	*****	1.00	*****	1.00	68,250,982	0.00	5,593,486.0
October	*****	*****	1.00	*****	1.00	68,415,986	0.00	5,794,131.9
November	0	0	.	0	.	68,435,936	0.00	5,609,779.7
December	*****	*****	1.00	*****	1.00	68,475,795	0.00	5,801,670.7
2016								
January	*****	*****	1.00	*****	1.00	47,580,163	0.00	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.00	3,772,301.8
March	*****	*****	1.00	*****	1.00	47,828,623	0.00	4,042,407.0
April	*****	*****	5.00	*****	5.00	47,635,110	0.00	3,900,491.1
May	0	0	.	0	.	47,635,453	0.00	4,030,105.5
June	*****	*****	2.00	*****	2.00	47,640,364	0.00	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.00	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.00	4,033,197.3
September	*****	*****	1.00	*****	1.00	47,757,059	0.00	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	.	0		47,818,224	0.00	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.00	3,917,112.2
December	*****	*****	1.33	*****	1.33	47,802,605	0.01	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.01	3,940,058.4
February	*****	*****	1.25	*****	1.25	45,511,150	0.01	3,479,143.0
March	*****	*****	1.00	*****	1.00	45,558,701	0.00	3,854,973.7
April	*****	*****	1.00	*****	1.00	45,514,720	0.00	3,727,264.6
May	*****	*****	1.00	*****	1.00	45,500,661	0.00	3,849,728.5
June	*****	*****	1.67	*****	1.67	45,494,736	0.01	3,724,607.3
July	*****	*****	1.00	*****	1.00	31,881,369	0.01	2,699,275.6
August	*****	*****	1.33	*****	1.33	31,652,890	0.01	2,680,329.5
September	*****	*****	1.25	*****	1.25	31,065,145	0.01	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	*****	*****	1.00	*****	1.00	12,479,435	0.01	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Zarxio NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	*****	*****	1.17	*****	-	47,580,163	0.01	4,023,276.5
February	*****	*****	1.20	*****	1.20	47,653,937	0.01	3,772,301.8
March	*****	*****	1.14	*****	1.14	47,828,623	0.01	4,042,407.0
April	*****	*****	1.20	*****	1.20	47,635,110	0.02	3,900,491.1
May	*****	*****	1.10	*****	1.10	47,635,453	0.02	4,030,105.5
June	11	19	1.73	19	1.73	47,640,364	0.02	3,900,051.3
July	*****	*****	1.13	*****	1.13	47,666,698	0.02	4,032,397.2
August	*****	*****	1.10	*****	1.10	47,717,017	0.02	4,033,197.3
September	*****	*****	1.38	*****	1.38	47,757,059	0.02	3,908,397.6
October	12	14	1.17	14	1.17	47,818,224	0.03	4,045,416.0
November	12	13	1.08	13	1.08	47,830,085	0.03	3,917,112.2
December	15	18	1.20	18	1.20	47,802,605	0.03	4,045,449.0
2017								
January	*****	*****	1.20	*****	1.20	46,591,044	0.02	3,940,058.4
February	20	22	1.10	22	1.10	45,511,150	0.04	3,479,143.0
March	18	23	1.28	23	1.28	45,558,701	0.04	3,854,973.7
April	20	23	1.15	23	1.15	45,514,720	0.04	3,727,264.6
May	19	27	1.42	27	1.42	45,500,661	0.04	3,849,728.5
June	13	18	1.38	18	1.38	45,494,736	0.03	3,724,607.3
July	11	14	1.27	14	1.27	31,881,369	0.03	2,699,275.6
August	13	17	1.31	17	1.31	31,652,890	0.04	2,680,329.5
September	14	16	1.14	16	1.14	31,065,145	0.05	2,545,744.9
October	*****	*****	1.00	*****	1.00	31,022,052	0.01	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	*****	*****	1.33	*****	1.33	12,479,435	0.02	1,024,760.4
December	*****	*****	1.00	*****	1.00	5,077,319	0.08	411,832.2
2018								
January	*****	*****	1.00	*****	1.00	702,371	0.14	59,600.0
J3490 + Remicade NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	*****	*****	1.17	*****	1.17	67,695,141	0.01	5,180,382.7
March	*****	*****	1.00	*****	1.00	68,122,569	0.01	5,769,793.3
April	*****	*****	1.00	*****	1.00	68,083,751	0.00	5,580,567.7
May	*****	*****	1.00	*****	1.00	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	*****	*****	1.00	*****	1.00	68,104,914	0.00	5,767,400.8
August	*****	*****	1.00	*****	1.00	68,207,920	0.00	5,773,795.7
September	*****	*****	1.00	*****	1.00	68,250,982	0.00	5,593,486.0
October	*****	*****	1.00	*****	1.00	68,415,986	0.01	5,794,131.9
November	*****	*****	1.00	*****	1.00	68,435,936	0.00	5,609,779.7
December	*****	*****	1.00	*****	1.00	68,475,795	0.01	5,801,670.7
2016								
January	*****	*****	1.00	*****	1.00	47,580,163	0.00	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.01	3,772,301.8
March	*****	*****	1.00	*****	1.00	47,828,623	0.01	4,042,407.0
April	*****	*****	1.00	*****	1.00	47,635,110	0.00	3,900,491.1
May	*****	*****	1.00	*****	1.00	47,635,453	0.01	4,030,105.5
June	*****	*****	1.00	*****	1.00	47,640,364	0.00	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.01	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.01	4,033,197.3
September	*****	*****	1.00	*****	1.00	47,757,059	0.00	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	*****	*****	1.00	*****	1.00	47,818,224	0.01	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.02	3,917,112.2
December	*****	*****	1.00	*****	1.00	47,802,605	0.01	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.01	3,940,058.4
February	*****	*****	1.00	*****	1.00	45,511,150	0.01	3,479,143.0
March	*****	*****	1.00	*****	1.00	45,558,701	0.01	3,854,973.7
April	*****	*****	1.00	*****	1.00	45,514,720	0.01	3,727,264.6
May	*****	*****	1.00	*****	1.00	45,500,661	0.01	3,849,728.5
June	*****	*****	1.00	*****	1.00	45,494,736	0.00	3,724,607.3
July	0	0	.	0		31,881,369	0.00	2,699,275.6
August	*****	*****	1.00	*****	1.00	31,652,890	0.01	2,680,329.5
September	*****	*****	1.00	*****	1.00	31,065,145	0.01	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	*****	*****	1.00	*****	1.00	12,479,435	0.01	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Inflectra NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Renflexis NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Neupogen NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	*****	*****	1.00	*****	1.00	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	*****	*****	1.00	*****	1.00	68,207,920	0.00	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	*****	*****	1.50	*****	1.50	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Neulasta NDCs								
2015								
January	*****	*****	1.00	*****	1.00	67,636,199	0.00	5,725,480.3
February	*****	*****	1.00	*****	1.00	67,695,141	0.00	5,180,382.7
March	*****	*****	1.00	*****	1.00	68,122,569	0.00	5,769,793.3
April	*****	*****	1.00	*****	1.00	68,083,751	0.00	5,580,567.7
May	0	0	.	0		68,106,988	0.00	5,768,682.4
June	*****	*****	1.00	*****	1.00	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	*****	*****	1.00	*****	1.00	68,415,986	0.00	5,794,131.9
November	*****	*****	1.00	*****	1.00	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	*****	*****	1.00	*****	1.00	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Granix NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Zarxio NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Remicade NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	*****	*****	1.00	*****	1.00	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	*****	*****	1.00	*****	1.00	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Inflectra NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Renflexis NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
Combinations, Same Day Dispensing and HCPCS								
J3490 + Neupogen NDCs								
2015								
January	17	17	1.00	17	1.00	67,636,199	0.03	5,725,480.3
February	20	24	1.20	24	1.20	67,695,141	0.03	5,180,382.7
March	22	28	1.27	28	1.27	68,122,569	0.03	5,769,793.3
April	25	31	1.24	31	1.24	68,083,751	0.04	5,580,567.7
May	31	34	1.10	34	1.10	68,106,988	0.05	5,768,682.4
June	18	22	1.22	22	1.22	68,069,693	0.03	5,578,913.0
July	18	20	1.11	20	1.11	68,104,914	0.03	5,767,400.8
August	16	18	1.13	18	1.13	68,207,920	0.02	5,773,795.7
September	17	21	1.24	21	1.24	68,250,982	0.02	5,593,486.0
October	20	25	1.25	25	1.25	68,415,986	0.03	5,794,131.9
November	*****	*****	1.10	*****	1.10	68,435,936	0.01	5,609,779.7
December	*****	*****	1.13	*****	1.13	68,475,795	0.02	5,801,670.7
2016								
January	*****	*****	1.33	*****	1.33	47,580,163	0.01	4,023,276.5
February	*****	*****	1.17	*****	1.17	47,653,937	0.01	3,772,301.8
March	*****	*****	1.00	*****	1.00	47,828,623	0.01	4,042,407.0
April	*****	*****	1.60	*****	1.60	47,635,110	0.01	3,900,491.1
May	*****	*****	1.67	*****	1.67	47,635,453	0.01	4,030,105.5
June	*****	*****	1.00	*****	1.00	47,640,364	0.01	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.02	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.01	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	*****	*****	1.25	*****	1.25	47,757,059	0.01	3,908,397.6
October	*****	*****	1.11	*****	1.11	47,818,224	0.02	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.01	3,917,112.2
December	*****	*****	1.17	*****	1.17	47,802,605	0.01	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.02	3,940,058.4
February	*****	*****	1.00	*****	1.00	45,511,150	0.01	3,479,143.0
March	*****	*****	1.25	*****	1.25	45,558,701	0.01	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	*****	*****	1.67	*****	1.67	45,500,661	0.01	3,849,728.5
June	*****	*****	1.00	*****	1.00	45,494,736	0.00	3,724,607.3
July	*****	*****	1.00	*****	1.00	31,881,369	0.01	2,699,275.6
August	*****	*****	1.20	*****	1.20	31,652,890	0.02	2,680,329.5
September	*****	*****	1.00	*****	1.00	31,065,145	0.00	2,545,744.9
October	*****	*****	1.25	*****	1.25	31,022,052	0.01	2,627,309.8
November	*****	*****	2.00	*****	2.00	12,479,435	0.02	1,024,760.4
December	*****	*****	1.00	*****	1.00	5,077,319	0.02	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Neulasta NDCs								
2015								
January	*****	*****	1.29	*****	1.29	67,636,199	0.01	5,725,480.3
February	*****	*****	1.10	*****	1.10	67,695,141	0.01	5,180,382.7
March	16	17	1.06	17	1.06	68,122,569	0.02	5,769,793.3
April	*****	*****	1.13	*****	1.13	68,083,751	0.01	5,580,567.7
May	*****	*****	1.11	*****	1.11	68,106,988	0.01	5,768,682.4
June	12	12	1.00	12	1.00	68,069,693	0.02	5,578,913.0
July	12	14	1.17	14	1.17	68,104,914	0.02	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	15	18	1.20	18	1.20	68,207,920	0.02	5,773,795.7
September	14	16	1.14	16	1.14	68,250,982	0.02	5,593,486.0
October	12	16	1.33	16	1.33	68,415,986	0.02	5,794,131.9
November	*****	*****	1.10	11	1.10	68,435,936	0.01	5,609,779.7
December	*****	*****	1.14	*****	1.14	68,475,795	0.01	5,801,670.7
2016								
January	*****	*****	1.00	*****	1.00	47,580,163	0.01	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.02	3,772,301.8
March	12	13	1.08	13	1.08	47,828,623	0.03	4,042,407.0
April	14	17	1.21	17	1.21	47,635,110	0.03	3,900,491.1
May	*****	*****	1.20	*****	1.20	47,635,453	0.02	4,030,105.5
June	15	16	1.07	16	1.07	47,640,364	0.03	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.02	4,032,397.2
August	11	13	1.18	13	1.18	47,717,017	0.02	4,033,197.3
September	*****	*****	1.00	*****	1.00	47,757,059	0.01	3,908,397.6
October	*****	*****	1.22	*****	1.22	47,818,224	0.02	4,045,416.0
November	*****	*****	1.25	*****	1.25	47,830,085	0.02	3,917,112.2
December	*****	*****	1.40	*****	1.40	47,802,605	0.01	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.02	3,940,058.4
February	*****	*****	1.57	*****	1.57	45,511,150	0.02	3,479,143.0
March	*****	*****	1.11	*****	1.11	45,558,701	0.02	3,854,973.7
April	*****	*****	1.00	*****	1.00	45,514,720	0.02	3,727,264.6
May	*****	*****	1.11	*****	1.11	45,500,661	0.02	3,849,728.5
June	*****	*****	1.25	*****	1.25	45,494,736	0.02	3,724,607.3
July	*****	*****	1.00	*****	1.00	31,881,369	0.02	2,699,275.6
August	*****	*****	1.33	*****	1.33	31,652,890	0.01	2,680,329.5
September	*****	*****	1.40	*****	1.40	31,065,145	0.02	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	*****	*****	1.00	*****	1.00	31,022,052	0.02	2,627,309.8
November	*****	*****	1.00	*****	1.00	12,479,435	0.02	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Granix NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	*****	*****	1.00	*****	1.00	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	*****	*****	1.00	*****	1.00	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	*****	*****	1.00	*****	1.00	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	*****	*****	1.00	*****	1.00	47,828,623	0.00	4,042,407.0
April	*****	*****	1.00	*****	1.00	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.00	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.00	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.00	3,917,112.2
December	*****	*****	1.00	*****	1.00	47,802,605	0.00	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.00	3,940,058.4
February	*****	*****	1.00	*****	1.00	45,511,150	0.01	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	*****	*****	1.33	*****	1.33	45,494,736	0.01	3,724,607.3
July	*****	*****	1.00	*****	1.00	31,881,369	0.01	2,699,275.6
August	*****	*****	1.00	*****	1.00	31,652,890	0.00	2,680,329.5
September	*****	*****	1.00	*****	1.00	31,065,145	0.01	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Zarxio NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	*****	*****	1.25	*****	1.25	47,580,163	0.01	4,023,276.5
February	*****	*****	1.20	*****	1.20	47,653,937	0.01	3,772,301.8
March	*****	*****	1.17	*****	1.17	47,828,623	0.01	4,042,407.0
April	*****	*****	1.14	*****	1.14	47,635,110	0.01	3,900,491.1
May	*****	*****	1.17	*****	1.17	47,635,453	0.01	4,030,105.5
June	*****	*****	1.56	*****	1.56	47,640,364	0.02	3,900,051.3
July	*****	*****	1.25	*****	1.25	47,666,698	0.01	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.01	4,033,197.3
September	*****	*****	1.33	*****	1.33	47,757,059	0.01	3,908,397.6
October	*****	*****	1.25	*****	1.25	47,818,224	0.02	4,045,416.0
November	*****	*****	1.13	*****	1.13	47,830,085	0.02	3,917,112.2
December	*****	*****	1.17	*****	1.17	47,802,605	0.01	4,045,449.0
2017								
January	*****	*****	1.17	*****	1.17	46,591,044	0.01	3,940,058.4
February	11	11	1.00	11	1.00	45,511,150	0.02	3,479,143.0
March	*****	*****	1.20	*****	1.20	45,558,701	0.02	3,854,973.7
April	11	12	1.09	12	1.09	45,514,720	0.02	3,727,264.6
May	14	16	1.14	16	1.14	45,500,661	0.03	3,849,728.5
June	*****	*****	1.43	*****	1.43	45,494,736	0.02	3,724,607.3
July	*****	*****	1.30	*****	1.30	31,881,369	0.03	2,699,275.6
August	*****	*****	1.30	*****	1.30	31,652,890	0.03	2,680,329.5
September	*****	*****	1.11	*****	1.11	31,065,145	0.03	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	*****	*****	1.50	*****	1.50	12,479,435	0.02	1,024,760.4
December	*****	*****	1.00	*****	1.00	5,077,319	0.04	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Remicade NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	*****	*****	1.00	*****	1.00	67,695,141	0.00	5,180,382.7
March	*****	*****	1.00	*****	1.00	68,122,569	0.00	5,769,793.3
April	*****	*****	1.00	*****	1.00	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	*****	*****	1.00	*****	1.00	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	*****	*****	1.00	*****	1.00	68,250,982	0.00	5,593,486.0
October	*****	*****	1.00	*****	1.00	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	*****	*****	1.00	*****	1.00	47,580,163	0.00	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.00	3,772,301.8
March	*****	*****	1.00	*****	1.00	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	*****	*****	1.00	*****	1.00	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	*****	*****	1.00	*****	1.00	47,666,698	0.00	4,032,397.2
August	*****	*****	1.00	*****	1.00	47,717,017	0.00	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	*****	*****	1.00	*****	1.00	47,818,224	0.00	4,045,416.0
November	*****	*****	1.00	*****	1.00	47,830,085	0.00	3,917,112.2
December	*****	*****	1.00	*****	1.00	47,802,605	0.00	4,045,449.0
2017								
January	*****	*****	1.00	*****	1.00	46,591,044	0.01	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	*****	*****	1.00	*****	1.00	45,558,701	0.00	3,854,973.7
April	*****	*****	1.00	*****	1.00	45,514,720	0.00	3,727,264.6
May	*****	*****	1.00	*****	1.00	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	*****	*****	1.00	*****	1.00	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Inflectra NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3490 + Renflexis NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Neupogen NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	*****	*****	1.00	*****	1.00	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Neulasta NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Granix NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Zarxio NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Remicade NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Inflectra NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0
J3590 + Renflexis NDCs								
2015								
January	0	0	-	0	-	67,636,199	0.00	5,725,480.3
February	0	0	-	0	-	67,695,141	0.00	5,180,382.7
March	0	0	-	0	-	68,122,569	0.00	5,769,793.3
April	0	0	-	0	-	68,083,751	0.00	5,580,567.7
May	0	0	-	0	-	68,106,988	0.00	5,768,682.4
June	0	0	-	0	-	68,069,693	0.00	5,578,913.0
July	0	0	-	0	-	68,104,914	0.00	5,767,400.8

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
August	0	0	-	0	-	68,207,920	0.00	5,773,795.7
September	0	0	-	0	-	68,250,982	0.00	5,593,486.0
October	0	0	-	0	-	68,415,986	0.00	5,794,131.9
November	0	0	-	0	-	68,435,936	0.00	5,609,779.7
December	0	0	-	0	-	68,475,795	0.00	5,801,670.7
2016								
January	0	0	-	0	-	47,580,163	0.00	4,023,276.5
February	0	0	-	0	-	47,653,937	0.00	3,772,301.8
March	0	0	-	0	-	47,828,623	0.00	4,042,407.0
April	0	0	-	0	-	47,635,110	0.00	3,900,491.1
May	0	0	-	0	-	47,635,453	0.00	4,030,105.5
June	0	0	-	0	-	47,640,364	0.00	3,900,051.3
July	0	0	-	0	-	47,666,698	0.00	4,032,397.2
August	0	0	-	0	-	47,717,017	0.00	4,033,197.3
September	0	0	-	0	-	47,757,059	0.00	3,908,397.6
October	0	0	-	0	-	47,818,224	0.00	4,045,416.0
November	0	0	-	0	-	47,830,085	0.00	3,917,112.2
December	0	0	-	0	-	47,802,605	0.00	4,045,449.0
2017								
January	0	0	-	0	-	46,591,044	0.00	3,940,058.4
February	0	0	-	0	-	45,511,150	0.00	3,479,143.0
March	0	0	-	0	-	45,558,701	0.00	3,854,973.7
April	0	0	-	0	-	45,514,720	0.00	3,727,264.6
May	0	0	-	0	-	45,500,661	0.00	3,849,728.5
June	0	0	-	0	-	45,494,736	0.00	3,724,607.3
July	0	0	-	0	-	31,881,369	0.00	2,699,275.6
August	0	0	-	0	-	31,652,890	0.00	2,680,329.5
September	0	0	-	0	-	31,065,145	0.00	2,545,744.9

Table 2. Summary of Prevalent Use of Biologics and Biosimilars in Any Care Setting in the Sentinel Distributed Database between January 1, 2015 and January 31, 2018, by Year and Month

	Patients	Episodes	Number of Episodes per Patient	Adjusted Dispensings ¹	Number of Dispensings per Patient	Eligible Members ²	Number of Exposed Members per 100,000 Eligible Members	Eligible Member-Years ²
October	0	0	-	0	-	31,022,052	0.00	2,627,309.8
November	0	0	-	0	-	12,479,435	0.00	1,024,760.4
December	0	0	-	0	-	5,077,319	0.00	411,832.2
2018								
January	0	0	-	0	-	702,371	0.00	59,600.0

¹ Adjusted dispensings allow one dispensing with the same generic name per day.

² Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Baseline Characteristics Users of Remicade in the Sentinel Distributed Database (SDD) between January 1, 2015 to January 31, 2018

Characteristic	Number	Percent
Number of episodes	64,487	100%
Number of unique patients	64,487	100%
Demographics ¹	Mean	Standard Deviation
Mean Age (years)	52.2	16.4
Age (years)	Number	Percent
0-64	43,899	68.1%
65+	20,588	31.9%
Sex		
Female	38,587	59.8%
Male	*****	*****
Other	*****	*****
Year		
2015	47,535	73.7%
2016	9,786	15.2%
2017	7,143	11.1%
2018	23	0.0%
Recorded history of Characteristics in the 365 days prior to index ² :	Number	Percent
GI conditions	33,078	51.3%
Non-GI conditions	33,276	51.6%
No GI conditions and no Non-GI conditions	1,828	2.8%
Recorded history of Characteristics in the 365 days prior to and 365 days after index ² :	Number	Percent
GI conditions	33,425	51.8%
Non-GI conditions	34,458	53.4%
No GI conditions and no Non-GI conditions	1,598	2.5%

¹Counts of number of new users per year could be influenced by various factors including availability of Data Partner data (Appendix A), market entries, and discontinuations of product

²Addition of GI conditions, Non-GI conditions and neither GI or Non-GI won't produce 100% due to some patients having both a GI and a Non-GI condition.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Baseline Characteristics Users of Inflectra in the Sentinel Distributed Database (SDD) between January 1, 2015 to January 31, 2018

Characteristic	Number	Percent
Number of episodes	141	100%
Number of unique patients	141	100%
Demographics ¹	Mean	Standard Deviation
Mean Age (years)	59.1	15.6
Age (years)	Number	Percent
0-64	73	51.8%
65+	68	48.2%
Sex		
Female	89	63.1%
Male	52	36.9%
Other	0	0.0%
Year		
2015	0	0.0%
2016	0	0.0%
2017	141	100.0%
2018	0	0.0%
Recorded history of Characteristics in the 365 days prior to index ² :	Number	Percent
GI conditions	19	13.5%
Non-GI conditions	113	80.1%
No GI conditions and no Non-GI conditions	13	9.2%
Recorded history of Characteristics in the 365 days prior to and 365 days after index ² :	Number	Percent
GI conditions	19	13.5%
Non-GI conditions	113	80.1%
No GI conditions and no Non-GI conditions	13	9.2%

¹Counts of number of new users per year could be influenced by various factors including availability of Data Partner data (Appendix A), market entries, and discontinuations of product

²Addition of GI conditions, Non-GI conditions and neither GI or Non-GI won't produce 100% due to some patients having both a GI and a Non-GI condition.

Table 3c. Baseline Characteristics Users of Renflexis in the Sentinel Distributed Database (SDD) between January 1, 2015 to January 31, 2018

Characteristic	Number	Percent
Number of episodes	-	-
Number of unique patients	-	-
Demographics ¹	Mean	Standard Deviation
Mean Age (years)	-	-
Age (years)	Number	Percent
0-64	-	-
65+	-	-
Sex		
Female	-	-
Male	-	-
Other	-	-
Year		
2015	-	-
2016	-	-
2017	-	-
2018	-	-
Recorded history of Characteristics in the 365 days prior to index ² :	Number	Percent
GI conditions	-	-
Non-GI conditions	-	-
No GI conditions and no Non-GI conditions	-	-
Recorded history of Characteristics in the 365 days prior to and 365 days after index ² :	Number	Percent
GI conditions	-	-
Non-GI conditions	-	-
No GI conditions and no Non-GI conditions	-	-

¹Counts of number of new users per year could be influenced by various factors including availability of Data Partner data (Appendix A), market entries, and discontinuations of product

²Addition of GI conditions, Non-GI conditions and neither GI or Non-GI won't produce 100% due to some patients having both a GI and a Non-GI condition.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 31, 2018)

Masked ID	DP Start Date*	DP End Date*
DP01	01/01/2000	03/31/2016
DP02	06/01/2007	10/31/2017
DP03	01/01/2000	12/31/2017
DP04	01/01/2008	11/30/2017
DP05	01/01/2006	10/31/2017
DP06	01/01/2000	12/31/2016
DP07	01/01/2008	06/30/2017
DP08	01/01/2010	12/31/2015
DP09	01/01/2000	07/31/2017
DP10	01/01/2000	05/31/2015
DP11	01/01/2000	01/31/2017
DP12	01/01/2000	10/31/2017
DP13	01/01/2005	12/17/2017
DP14	01/01/2004	01/31/2018
DP15	01/01/2000	08/31/2017
DP16	01/01/2000	06/30/2017
DP17	01/01/2012	06/30/2017

* The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month

Appendix B. List of Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures of Interest in this Request

Code	Description	Brand Name	Code Type
J3490	Unclassified Drugs & Injections	-	HCPCS
J3590	Unclassified biologics	-	HCPCS
J1440	Injection, filgrastim (g-csf), 300 mcg	Neupogen	HCPCS
J1441	Injection, filgrastim (g-csf), 480 mcg	Neupogen	HCPCS
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	Neupogen	HCPCS
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram	Zarxio	HCPCS
J2505	Injection, pegfilgrastim, 6 mg	Neulasta	HCPCS
J1446	Injection, tbo-filgrastim, 5 mcg	Granix	HCPCS
J1447	Injection, tbo-filgrastim, 1 mcg	Granix	HCPCS
J1745	Injection, infliximab, excludes biosimilar, 10 mg	Remicade	HCPCS
Q5102	Injection, infliximab, biosimilar, 10 mg	-	HCPCS

Appendix C. List of Non-Proprietary and Brand Names of Medical Products Used to Define Exposures of Interest in this Request

Non-Proprietary Name	Brand Name
Infliximab-Abda	Renflexis
Infliximab-Dyyb	Inflectra
Pegfilgrastim	Neulasta
Filgrastim	Neupogen
Infliximab	Remicade
Filgrastim-Sndz	Zarxio
Tbo-Filbrastim	Granix

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Gastrointestinal (GI) Conditions			
555	Regional enteritis	Diagnosis	ICD-9-CM
555.1	Regional enteritis of large intestine	Diagnosis	ICD-9-CM
555.0	Regional enteritis of small intestine	Diagnosis	ICD-9-CM
555.9	Regional enteritis of unspecified site	Diagnosis	ICD-9-CM
555.2	Regional enteritis of small intestine with large intestine	Diagnosis	ICD-9-CM
556	Ulcerative colitis	Diagnosis	ICD-9-CM
556.0	Ulcerative (chronic) enterocolitis	Diagnosis	ICD-9-CM
556.1	Ulcerative (chronic) ileocolitis	Diagnosis	ICD-9-CM
556.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-9-CM
556.3	Ulcerative (chronic) proctosigmoiditis	Diagnosis	ICD-9-CM
556.4	Pseudopolyposis of colon	Diagnosis	ICD-9-CM
556.5	Left sided ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.6	Universal ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.8	Other ulcerative colitis	Diagnosis	ICD-9-CM
556.9	Unspecified ulcerative colitis	Diagnosis	ICD-9-CM
K51.8	Other ulcerative colitis	Diagnosis	ICD-10-CM
K51.814	Other ulcerative colitis with abscess	Diagnosis	ICD-10-CM
K51.81	Other ulcerative colitis with complications	Diagnosis	ICD-10-CM
K51.813	Other ulcerative colitis with fistula	Diagnosis	ICD-10-CM
K51.812	Other ulcerative colitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.818	Other ulcerative colitis with other complication	Diagnosis	ICD-10-CM
K51.811	Other ulcerative colitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.819	Other ulcerative colitis with unspecified complications	Diagnosis	ICD-10-CM
K51.80	Other ulcerative colitis without complications	Diagnosis	ICD-10-CM
K51.0	Ulcerative (chronic) pancolitis	Diagnosis	ICD-10-CM
K51.014	Ulcerative (chronic) pancolitis with abscess	Diagnosis	ICD-10-CM
K51.01	Ulcerative (chronic) pancolitis with complications	Diagnosis	ICD-10-CM
K51.013	Ulcerative (chronic) pancolitis with fistula	Diagnosis	ICD-10-CM
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.018	Ulcerative (chronic) pancolitis with other complication	Diagnosis	ICD-10-CM
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.019	Ulcerative (chronic) pancolitis with unspecified complications	Diagnosis	ICD-10-CM
K51.00	Ulcerative (chronic) pancolitis without complications	Diagnosis	ICD-10-CM
K51.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-10-CM
K51.214	Ulcerative (chronic) proctitis with abscess	Diagnosis	ICD-10-CM
K51.21	Ulcerative (chronic) proctitis with complications	Diagnosis	ICD-10-CM
K51.213	Ulcerative (chronic) proctitis with fistula	Diagnosis	ICD-10-CM
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.218	Ulcerative (chronic) proctitis with other complication	Diagnosis	ICD-10-CM
K51.211	Ulcerative (chronic) proctitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.219	Ulcerative (chronic) proctitis with unspecified complications	Diagnosis	ICD-10-CM
K51.20	Ulcerative (chronic) proctitis without complications	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
K51.3	Ulcerative (chronic) rectosigmoiditis	Diagnosis	ICD-10-CM
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess	Diagnosis	ICD-10-CM
K51.31	Ulcerative (chronic) rectosigmoiditis with complications	Diagnosis	ICD-10-CM
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula	Diagnosis	ICD-10-CM
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication	Diagnosis	ICD-10-CM
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding	Diagnosis	ICD-10-CM
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications	Diagnosis	ICD-10-CM
K51.30	Ulcerative (chronic) rectosigmoiditis without complications	Diagnosis	ICD-10-CM
K51.9	Ulcerative colitis, unspecified	Diagnosis	ICD-10-CM
K51.914	Ulcerative colitis, unspecified with abscess	Diagnosis	ICD-10-CM
K51.913	Ulcerative colitis, unspecified with fistula	Diagnosis	ICD-10-CM
K51.912	Ulcerative colitis, unspecified with intestinal obstruction	Diagnosis	ICD-10-CM
K51.918	Ulcerative colitis, unspecified with other complication	Diagnosis	ICD-10-CM
K51.911	Ulcerative colitis, unspecified with rectal bleeding	Diagnosis	ICD-10-CM
K51.919	Ulcerative colitis, unspecified with unspecified complications	Diagnosis	ICD-10-CM
K51.91	Ulcerative colitis, unspecified, with complications	Diagnosis	ICD-10-CM
K51.90	Ulcerative colitis, unspecified, without complications	Diagnosis	ICD-10-CM
K50.8	Crohn's disease of both small and large intestine	Diagnosis	ICD-10-CM
K50.814	Crohn's disease of both small and large intestine with abscess	Diagnosis	ICD-10-CM
K50.81	Crohn's disease of both small and large intestine with complications	Diagnosis	ICD-10-CM
K50.813	Crohn's disease of both small and large intestine with fistula	Diagnosis	ICD-10-CM
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.818	Crohn's disease of both small and large intestine with other complication	Diagnosis	ICD-10-CM
K50.811	Crohn's disease of both small and large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.819	Crohn's disease of both small and large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.80	Crohn's disease of both small and large intestine without complications	Diagnosis	ICD-10-CM
K50.1	Crohn's disease of large intestine	Diagnosis	ICD-10-CM
K50.114	Crohn's disease of large intestine with abscess	Diagnosis	ICD-10-CM
K50.11	Crohn's disease of large intestine with complications	Diagnosis	ICD-10-CM
K50.113	Crohn's disease of large intestine with fistula	Diagnosis	ICD-10-CM
K50.112	Crohn's disease of large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.118	Crohn's disease of large intestine with other complication	Diagnosis	ICD-10-CM
K50.111	Crohn's disease of large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.119	Crohn's disease of large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.10	Crohn's disease of large intestine without complications	Diagnosis	ICD-10-CM
K50.0	Crohn's disease of small intestine	Diagnosis	ICD-10-CM
K50.014	Crohn's disease of small intestine with abscess	Diagnosis	ICD-10-CM
K50.01	Crohn's disease of small intestine with complications	Diagnosis	ICD-10-CM
K50.013	Crohn's disease of small intestine with fistula	Diagnosis	ICD-10-CM
K50.012	Crohn's disease of small intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.018	Crohn's disease of small intestine with other complication	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
K50.011	Crohn's disease of small intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.019	Crohn's disease of small intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.00	Crohn's disease of small intestine without complications	Diagnosis	ICD-10-CM
K50.9	Crohn's disease, unspecified	Diagnosis	ICD-10-CM
K50.914	Crohn's disease, unspecified, with abscess	Diagnosis	ICD-10-CM
K50.91	Crohn's disease, unspecified, with complications	Diagnosis	ICD-10-CM
K50.913	Crohn's disease, unspecified, with fistula	Diagnosis	ICD-10-CM
K50.912	Crohn's disease, unspecified, with intestinal obstruction	Diagnosis	ICD-10-CM
K50.918	Crohn's disease, unspecified, with other complication	Diagnosis	ICD-10-CM
K50.911	Crohn's disease, unspecified, with rectal bleeding	Diagnosis	ICD-10-CM
K50.919	Crohn's disease, unspecified, with unspecified complications	Diagnosis	ICD-10-CM
K50.90	Crohn's disease, unspecified, without complications	Diagnosis	ICD-10-CM
Non-Gastrointestinal (Non-GI) Conditions			
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714	Rheumatoid arthritis and other inflammatory polyarthropathies	Diagnosis	ICD-9-CM
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
720	Ankylosing spondylitis and other inflammatory spondylopathies	Diagnosis	ICD-9-CM
696.0	Psoriatic arthritis (PsA) Psoriatic arthropathy	Diagnosis	ICD-9-CM
696.8	Psoriasis related disease NEC	Diagnosis	ICD-9-CM
696.1	Other psoriasis	Diagnosis	ICD-9-CM
696	Psoriasis and similar disorders	Diagnosis	ICD-9-CM
M08.27	Juvenile rheumatoid arthritis with systemic onset, ankle and foot	Diagnosis	ICD-10-CM
M08.22	Juvenile rheumatoid arthritis with systemic onset, elbow	Diagnosis	ICD-10-CM
M08.24	Juvenile rheumatoid arthritis with systemic onset, hand	Diagnosis	ICD-10-CM
M08.25	Juvenile rheumatoid arthritis with systemic onset, hip	Diagnosis	ICD-10-CM
M08.26	Juvenile rheumatoid arthritis with systemic onset, knee	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.21	Juvenile rheumatoid arthritis with systemic onset, shoulder	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.23	Juvenile rheumatoid arthritis with systemic onset, wrist	Diagnosis	ICD-10-CM
M05.8	Other rheumatoid arthritis with rheumatoid factor	Diagnosis	ICD-10-CM
M05.87	Other rheumatoid arthritis with rheumatoid factor of ankle and foot	Diagnosis	ICD-10-CM
M05.82	Other rheumatoid arthritis with rheumatoid factor of elbow	Diagnosis	ICD-10-CM
M05.84	Other rheumatoid arthritis with rheumatoid factor of hand	Diagnosis	ICD-10-CM
M05.85	Other rheumatoid arthritis with rheumatoid factor of hip	Diagnosis	ICD-10-CM
M05.86	Other rheumatoid arthritis with rheumatoid factor of knee	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.81	Other rheumatoid arthritis with rheumatoid factor of shoulder	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.83	Other rheumatoid arthritis with rheumatoid factor of wrist	Diagnosis	ICD-10-CM
M06.8	Other specified rheumatoid arthritis	Diagnosis	ICD-10-CM
M06.87	Other specified rheumatoid arthritis, ankle and foot	Diagnosis	ICD-10-CM
M06.82	Other specified rheumatoid arthritis, elbow	Diagnosis	ICD-10-CM
M06.84	Other specified rheumatoid arthritis, hand	Diagnosis	ICD-10-CM
M06.85	Other specified rheumatoid arthritis, hip	Diagnosis	ICD-10-CM
M06.86	Other specified rheumatoid arthritis, knee	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.81	Other specified rheumatoid arthritis, shoulder	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.83	Other specified rheumatoid arthritis, wrist	Diagnosis	ICD-10-CM
M08.4	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-10-CM
M08.47	Pauciarticular juvenile rheumatoid arthritis, ankle and foot	Diagnosis	ICD-10-CM
M08.42	Pauciarticular juvenile rheumatoid arthritis, elbow	Diagnosis	ICD-10-CM
M08.44	Pauciarticular juvenile rheumatoid arthritis, hand	Diagnosis	ICD-10-CM
M08.45	Pauciarticular juvenile rheumatoid arthritis, hip	Diagnosis	ICD-10-CM
M08.46	Pauciarticular juvenile rheumatoid arthritis, knee	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.41	Pauciarticular juvenile rheumatoid arthritis, shoulder	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.43	Pauciarticular juvenile rheumatoid arthritis, wrist	Diagnosis	ICD-10-CM
M05.67	Rheumatoid arthritis of ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.62	Rheumatoid arthritis of elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.64	Rheumatoid arthritis of hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.65	Rheumatoid arthritis of hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.66	Rheumatoid arthritis of knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.61	Rheumatoid arthritis of shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.63	Rheumatoid arthritis of wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.6	Rheumatoid arthritis with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.77	Rheumatoid arthritis with rheumatoid factor of ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.72	Rheumatoid arthritis with rheumatoid factor of elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.74	Rheumatoid arthritis with rheumatoid factor of hand without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.75	Rheumatoid arthritis with rheumatoid factor of hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.76	Rheumatoid arthritis with rheumatoid factor of knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.71	Rheumatoid arthritis with rheumatoid factor of shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.73	Rheumatoid arthritis with rheumatoid factor of wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.0	Rheumatoid arthritis without rheumatoid factor	Diagnosis	ICD-10-CM
M06.07	Rheumatoid arthritis without rheumatoid factor, ankle and foot	Diagnosis	ICD-10-CM
M06.02	Rheumatoid arthritis without rheumatoid factor, elbow	Diagnosis	ICD-10-CM
M06.04	Rheumatoid arthritis without rheumatoid factor, hand	Diagnosis	ICD-10-CM
M06.05	Rheumatoid arthritis without rheumatoid factor, hip	Diagnosis	ICD-10-CM
M06.06	Rheumatoid arthritis without rheumatoid factor, knee	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.01	Rheumatoid arthritis without rheumatoid factor, shoulder	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.03	Rheumatoid arthritis without rheumatoid factor, wrist	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M06.2	Rheumatoid bursitis	Diagnosis	ICD-10-CM
M06.27	Rheumatoid bursitis, ankle and foot	Diagnosis	ICD-10-CM
M06.22	Rheumatoid bursitis, elbow	Diagnosis	ICD-10-CM
M06.24	Rheumatoid bursitis, hand	Diagnosis	ICD-10-CM
M06.25	Rheumatoid bursitis, hip	Diagnosis	ICD-10-CM
M06.26	Rheumatoid bursitis, knee	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.21	Rheumatoid bursitis, shoulder	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.23	Rheumatoid bursitis, wrist	Diagnosis	ICD-10-CM
M05.3	Rheumatoid heart disease with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.37	Rheumatoid heart disease with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.32	Rheumatoid heart disease with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.34	Rheumatoid heart disease with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.35	Rheumatoid heart disease with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.36	Rheumatoid heart disease with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.31	Rheumatoid heart disease with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.33	Rheumatoid heart disease with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.1	Rheumatoid lung disease with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.17	Rheumatoid lung disease with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.12	Rheumatoid lung disease with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.14	Rheumatoid lung disease with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.15	Rheumatoid lung disease with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.16	Rheumatoid lung disease with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.11	Rheumatoid lung disease with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.13	Rheumatoid lung disease with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.4	Rheumatoid myopathy with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.47	Rheumatoid myopathy with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.42	Rheumatoid myopathy with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.44	Rheumatoid myopathy with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.45	Rheumatoid myopathy with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.46	Rheumatoid myopathy with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.41	Rheumatoid myopathy with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.43	Rheumatoid myopathy with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M06.3	Rheumatoid nodule	Diagnosis	ICD-10-CM
M06.37	Rheumatoid nodule, ankle and foot	Diagnosis	ICD-10-CM
M06.32	Rheumatoid nodule, elbow	Diagnosis	ICD-10-CM
M06.34	Rheumatoid nodule, hand	Diagnosis	ICD-10-CM
M06.35	Rheumatoid nodule, hip	Diagnosis	ICD-10-CM
M06.36	Rheumatoid nodule, knee	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.31	Rheumatoid nodule, shoulder	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.33	Rheumatoid nodule, wrist	Diagnosis	ICD-10-CM
M05.5	Rheumatoid polyneuropathy with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.57	Rheumatoid polyneuropathy with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.52	Rheumatoid polyneuropathy with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.54	Rheumatoid polyneuropathy with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.55	Rheumatoid polyneuropathy with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.56	Rheumatoid polyneuropathy with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.51	Rheumatoid polyneuropathy with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.53	Rheumatoid polyneuropathy with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.2	Rheumatoid vasculitis with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.27	Rheumatoid vasculitis with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.22	Rheumatoid vasculitis with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.24	Rheumatoid vasculitis with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.25	Rheumatoid vasculitis with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.26	Rheumatoid vasculitis with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.21	Rheumatoid vasculitis with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.23	Rheumatoid vasculitis with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M08.0	Unspecified juvenile rheumatoid arthritis	Diagnosis	ICD-10-CM
M08.02	Unspecified juvenile rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.07	Unspecified juvenile rheumatoid arthritis, ankle and foot	Diagnosis	ICD-10-CM
M08.04	Unspecified juvenile rheumatoid arthritis, hand	Diagnosis	ICD-10-CM
M08.05	Unspecified juvenile rheumatoid arthritis, hip	Diagnosis	ICD-10-CM
M08.06	Unspecified juvenile rheumatoid arthritis, knee	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.01	Unspecified juvenile rheumatoid arthritis, shoulder	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.03	Unspecified juvenile rheumatoid arthritis, wrist	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
L40.52	Psoriatic arthritis mutilans	Diagnosis	ICD-10-CM
L40.5	Arthropathic psoriasis	Diagnosis	ICD-10-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.1	Generalized pustular psoriasis	Diagnosis	ICD-10-CM
L40.4	Guttate psoriasis	Diagnosis	ICD-10-CM
L40.8	Other psoriasis	Diagnosis	ICD-10-CM
L40.0	Psoriasis vulgaris	Diagnosis	ICD-10-CM
L40.9	Psoriasis, unspecified	Diagnosis	ICD-10-CM

Appendix E. Specifications Defining Parameters in the Request

This exploratory study aimed to understand how biosimilars are coded for reimbursement, and therefore appear in claims data. This request utilized the Cohort Identification and Descriptive Analysis (CIDA) module, version 5.4.3 to assess patient exposure to select biologics and their biosimilars in Sentinel Distributed Database (SDD).

Query Period: January 1, 2015 - January 31, 2018
Enrollment Gap: 45 days
Age Groups: All ages to be included
Enrollment Requirement: 365 days
Coverage Requirement: Medical and Drug Coverage

Scenario	Exposure					Baseline Characteristics				
	Exposure	Time Interval Between	Washout (days)	Incidence Criteria	Cohort Definition	Care Setting	Enrollment Requirement (days)	Characteristics	Care Setting	Evaluation Window (days)
1	Neupogen (J1440)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
2	Neupogen (J1441)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
3	Neupogen (J1442)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
4	Zarxio (Q5101)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
5	Granix (J1446)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
6	Granix (J1447)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
7	Neulasta (J2505)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
8	Neupogen (National Drug Codes: NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
9	Zarxio (NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
10	Granix (NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-

Appendix E. Specifications Defining Parameters in the Request

Scenario	Exposure					Baseline Characteristics				
	Exposure	Time Interval Between	Washout (days)	Incidence Criteria	Cohort Definition	Care Setting	Enrollment Requirement (days)	Characteristics	Care Setting	Evaluation Window (days)
11	Neulasta (NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
12	Remicade(J1745)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
13	Infliximab biosimilar (Q5102)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
14	Remicade (NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
15	Infectra (NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
16	Renflexis (NDCs)	n/a	0	None	Include all valid index dates per individual	Any	0	None	Any	-
17	Neupogen NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
18	Zarxio NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
19	Granix NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
20	Neulasta NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
21	Remicade NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
22	Infectra NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-

Appendix E. Specifications Defining Parameters in the Request

Scenario	Exposure					Baseline Characteristics				
	Exposure	Time Interval Between	Washout (days)	Incidence Criteria	Cohort Definition	Care Setting	Enrollment Requirement (days)	Characteristics	Care Setting	Evaluation Window (days)
23	Renflexis NDCs + J3490	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
24	Neupogen NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
25	Zarxio NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
26	Granix NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
27	Neulasta NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
28	Remicade NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
29	Inflectra NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
30	Renflexis NDCs + J3590	within +/- 3 days	0	None	Include all valid index dates per individual	Any	0	None	Any	-
31	Neupogen NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
32	Zarxio NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
33	Granix NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
34	Neulasta NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-

Appendix E. Specifications Defining Parameters in the Request

Scenario	Exposure					Baseline Characteristics				
	Exposure	Time Interval Between	Washout (days)	Incidence Criteria	Cohort Definition	Care Setting	Enrollment Requirement (days)	Characteristics	Care Setting	Evaluation Window (days)
35	Remicade NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
36	Inflectra NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
37	Renflexis NDCs + J3490	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
38	Neupogen NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
39	Zarxio NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
40	Granix NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
41	Neulasta NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
42	Remicade NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
43	Inflectra NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-
44	Renflexis NDCs + J3590	same day	0	None	Include all valid index dates per individual	Any	0	None	Any	-

Appendix E. Specifications Defining Parameters in the Request

Scenario	Exposure						Baseline Characteristics			
	Exposure	Time Interval Between	Washout (days)	Incidence Criteria	Cohort Definition	Care Setting	Enrollment Requirement (days)	Characteristics	Care Setting	Evaluation Window (days)
45	Remicade	n/a	0	None	Include only the first valid exposure episode per individual	Any	365	Gastrointestinal (GI) indications Non-GI indications	Any	-365, 0
								GI indications Non-GI indications	Any	-365, 365
								No GI and no Non-GI indications	Any	-365, 0
								No GI and no Non-GI indications	Any	-365, 365
46	Infectra	n/a	0	None	Include only the first valid exposure episode per individual	Any	365	GI indications Non-GI indications	Any	-365, 0
								GI indications Non-GI indications	Any	-365, 365
								No GI and no Non-GI indications	Any	-365, 0
								No GI and no Non-GI indications	Any	-365, 365

Appendix E. Specifications Defining Parameters in the Request

Scenario	Exposure							Baseline Characteristics		
	Exposure	Time Interval Between	Washout (days)	Incidence Criteria	Cohort Definition	Care Setting	Enrollment Requirement (days)	Characteristics	Care Setting	Evaluation Window (days)
47	Renflexis	n/a	0	None	Include only the first valid exposure episode per individual	Any	365	GI indications Non-GI indications	Any	-365, 0
								GI indications Non-GI indications	Any	-365, 365
								No GI and no Non-GI indications	Any	-365, 0
								No GI and no Non-GI indications	Any	-365, 365

International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) codes are provided by Optum360.
National Drug Codes (NDCs) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."